Trial reportBiological psychiatry. Cognitive neuroscience and neuroimaging2025
Effects of COMT Suppression in a Randomized Trial on the Neural Correlates of Inhibitory Processing Among People With Alcohol Use Disorder.
Trial report in Biological psychiatry. Cognitive neuroscience and neuroimaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
backgroundDysregulation of inhibitory control is a core feature of alcohol use disorder (AUD) and is mediated, in part, by catechol-O-methyltransferase (COMT) regulation of cortical dopaminergic neurotransmission. Tolcapone, a brain-penetrant COMT inhibitor, potentiates evoked dopamine release and may improve inhibitory control in AUD.
methodsNon-treatment-seeking participants with AUD (N = 64) were randomized to tolcapone (titrated to 200 mg three times a day) or placebo for 8 days and completed a functional magnetic resonance imaging stop signal task on study days 1 (prior to medication ingestion) and 7. Brain areas in which activation for the contrast of successful versus unsuccessful stop trials (stop success [SS]>stop error [SE]) differed between medication groups on day 7 relative to day 1 were identified. Activation of these areas and their functional connectivity with other areas were tested for association with changes in drinking during the medication period and with changes in stop signal reaction time, a behavioral index of inhibitory control.
resultsThe tolcapone group demonstrated greater SS>SE activation in the right dorsolateral prefrontal cortex and inferior frontal gyrus (iFG). In the tolcapone group, greater activation of both areas was associated with improved inhibitory control, and greater iFG activation was associated with reduced drinking. Increased connectivity between the iFG and right anterior insula was associated with reduced drinking, and increased connectivity between the iFG and anterior cingulate cortex was associated with improved inhibitory control.
conclusionsTolcapone increased activation of cortical areas implicated in inhibitory control. The associations between increased iFG activation and connectivity, improved inhibitory control, and reduced drinking suggest that pharmacological interventions that increase cortical dopamine may rescue dysregulated inhibitory control among people with AUD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.